Real-world utilization and acceptance of tacrolimus-based immunosuppression in solid organ transplant recipients in India

Abstract

<p><strong>Background:</strong> To describe the patient characteristics and usage pattern of biosimilar bevacizumab for the treatment of metastatic colorectal cancer (mCRC) in India.</p><p><strong>Methods:</strong> This real-world, retrospective analysis included adult patients receiving biosimilar bevacizumab between April 2021 and March 2022.</p><p><strong>Results:</strong> A total of 1125 patients with mCRC who received biosimilar bevacizumab-based chemotherapy were included. The mean age at diagnosis was 57.8 years. Majority of the patients were males (71%) and belonged to the age groups of 41-76 years. The primary tumor site was right colon (52.6%) followed by left colon (29.2%) and rectum (17.3%), and the tumor grade was reported as high in most (88.7%) of the patients. Majority of patients received biosimilar bevacizumab-based chemotherapy as first-line therapy (61.3%), followed by second-line (31.9%) and third-line therapy (6.8%). In combination with biosimilar bevacizumab, FOLFOX (folinic acid, 5-fluorouracil, and oxaliplatin) was the most commonly administered regimen (42.9%), followed by CAPOX (capecitabine and oxaliplatin, 26.5%) and FOLFIRI (folinic acid, 5-fluorouracil, and irinotecan, 22.8%).</p><p><strong>Conclusions:</strong> Biosimilar bevacizumab-based chemotherapy is being widely used in real‑world clinical setting in India for the management of patients with mCRC.</p>